Monthly
US$200
Billed every month
培哚普利氨氯地平片(III)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 3 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders20View records ↓
Under-review filings7View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers19View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 20 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 19 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 南京海纳制药有限公司 | 南京海纳制药有限公司 | 国药准字H20265857 | 2026/09/02 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（以C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川国为制药有限公司 | 四川国为制药有限公司 | 国药准字H20265185 | 2026/07/14 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江美迪深生物医药有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20264771 | 2026/06/10 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 任曦医药科技河北有限公司 | 石家庄龙泽制药股份有限公司 | 国药准字H20264500 | 2026/05/27 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南皇隆制药股份有限公司 | 海南皇隆制药股份有限公司 | 国药准字H20263791 | 2026/03/31 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东阳祥昇医药科技有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20263659 | 2026/03/17 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 桂林华信制药有限公司 | 桂林华信制药有限公司 | 国药准字H20263348 | 2026/02/02 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 厦门康泽瑞医药科技有限公司 | 双鹤天安药业（贵州）股份有限公司 | 国药准字H20263054 | 2026/01/14 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20256451 | 2025/12/30 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 远大医药（中国）有限公司 | 远大医药（中国）有限公司 | 国药准字H20256057 | 2025/11/25 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20255420 | 2025/09/09 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都硕德药业有限公司 | 成都硕德药业有限公司 | 国药准字H20254925 | 2025/07/22 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州康恩贝制药有限公司 | 杭州康恩贝制药有限公司 | 国药准字H20254915 | 2025/07/22 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天津力生制药股份有限公司 | 天津力生制药股份有限公司 | 国药准字H20254791 | 2025/07/08 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 江苏永安制药有限公司 | 国药准字H20254343 | 2025/05/27 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏济茗医药有限公司 | 江苏万高药业股份有限公司 | 国药准字H20253635 | 2025/03/18 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州市联瑞制药有限公司 | 江苏万高药业股份有限公司 | 国药准字H20249535 | 2024/12/01 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平（以氨氯地平计）5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| LES LABORATOIRES SERVIER | Servier (Ireland) Industries Ltd. | H20180015 | 2018/04/28 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg | Imported originator drug (进口原研药品) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20264659 | 2026/06/10 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（按C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海安必生制药技术有限公司 | 杭州民生滨江制药有限公司 | 国药准字H20266096 | 2026/09/29 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg（以C20H25ClN2O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 19 distinct approval numbers and 18 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 浙江华海药业股份有限公司 | 国药准字H20264659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010104647 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20263791 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010105781 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字J20190022 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010110288 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20264659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010204647 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20263791 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010205781 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字J20190022 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010210288 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20264659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010304647 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20263791 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010305781 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字J20190022 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010310288 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20264659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010404647 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字J20190022 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010410288 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20264659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010504647 | NHSA |
| 天津力生制药股份有限公司 | 国药准字H20254791 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010100886 | NHSA |
| 江苏济茗医药有限公司 | 国药准字H20253635 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010101503 | NHSA |
| 石家庄四药有限公司 | 国药准字H20256451 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010102763 | NHSA |
| 杭州康恩贝制药有限公司 | 国药准字H20254915 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅N₂O₅Cl计) | Category B (乙) | XC09BBP131A001010104489 | NHSA |
| 桂林华信制药有限公司 | 国药准字H20263348 | 每片含精氨酸培哚普利10mg、苯 磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010105199 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20255420 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010105356 | NHSA |
| 四川国为制药有限公司 | 国药准字H20265185 | 每片含精氨酸培哚普利 10mg、苯磺酸氨氯地平 5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010180937 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010183238 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H20256057 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010183383 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20254925 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅N₂O₅Cl计) | Category B (乙) | XC09BBP131A001010183830 | NHSA |
| 任曦医药科技河北有限公司 | 国药准字H20264500 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010183846 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20254343 | 每片含精氨酸培哚普利10mg、苯 磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010184221 | NHSA |
| 浙江美迪深生物医药有限公司 | 国药准字H20264771 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010184230 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20263659 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010184294 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20263054 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅ 计) | Category B (乙) | XC09BBP131A001010185500 | NHSA |
| 江苏济茗医药有限公司 | 国药准字H20253635 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010201503 | NHSA |
| 石家庄四药有限公司 | 国药准字H20256451 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010202763 | NHSA |
| 江西施美药业股份有限公司 | 国药准字H20255420 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010205356 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010283238 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20254925 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅N₂O₅Cl计) | Category B (乙) | XC09BBP131A001010283830 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20254343 | 每片含精氨酸培哚普利10mg、苯 磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010284221 | NHSA |
| 浙江美迪深生物医药有限公司 | 国药准字H20264771 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010284230 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20263054 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅ 计) | Category B (乙) | XC09BBP131A001010285500 | NHSA |
| 江苏济茗医药有限公司 | 国药准字H20253635 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010301503 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010383238 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20254925 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅N₂O₅Cl计) | Category B (乙) | XC09BBP131A001010383830 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20254343 | 每片含精氨酸培哚普利10mg、苯 磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010384221 | NHSA |
| 浙江美迪深生物医药有限公司 | 国药准字H20264771 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010384230 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20263054 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅ 计) | Category B (乙) | XC09BBP131A001010385500 | NHSA |
| 江苏济茗医药有限公司 | 国药准字H20253635 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010401503 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010483238 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20254343 | 每片含精氨酸培哚普利10mg、苯 磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010484221 | NHSA |
| 浙江美迪深生物医药有限公司 | 国药准字H20264771 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按 C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010484230 | NHSA |
| 江苏济茗医药有限公司 | 国药准字H20253635 | 每片含精氨酸培哚普利10mg、苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计) | Category B (乙) | XC09BBP131A001010501503 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字HJ20180015 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010579020 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010583238 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字HJ20180015 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010679020 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010683238 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字HJ20180015 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010779020 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010783238 | NHSA |
| LES LABORATOIRES SERVIER | 国药准字HJ20180015 | 每片含精氨酸培哚普利10mg和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010879020 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20249535 | 每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平(以氨氯地平 | Category B (乙) | XC09BBP131A001010883238 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 7 filings and 7 distinct first applicants.
Generic 5 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖南先施制药有限公司 | CYHS2600170 | Generic | 2026/01/14 | Not stated by source | CDE |
| 山西同达药业有限公司 | CYHB2502352 | Supplement | 2025/11/14 | Not stated by source | CDE |
| 浙江恒研医药科技有限公司;浙江赛默制药有限公司 | CYHS2503047 | Generic | 2025/08/19 | Not stated by source | CDE |
| 山东朗诺制药有限公司 | CYHS2502460 | Generic | 2025/07/10 | Not stated by source | CDE |
| 南京易亨制药有限公司 | CYHS2503748 | Generic | 2025/10/21 | Not stated by source | CDE |
| 国药集团致君（深圳）制药有限公司;国药集团致君（深圳）坪山制药有限公司 | CYHS2602512 | Generic | 2026/10/13 | Not stated by source | CDE |
| 天津力生制药股份有限公司 | CYHB2601706 | Supplement | 2026/09/09 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/04No longer listed under review
济宁神州医药有限公司;安徽佳和药业有限公司
CYHB2601553
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/08/14
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/03No longer listed under review
安徽佳和药业有限公司
CYHS2404520
Fact date: 2026/11/03 · Site observation date: 2026/11/03
Accepted: 2024/12/26
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/23No longer listed under review
淄博万杰制药有限公司
CYHS2504342
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2025/12/22
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/13Accepted
国药集团致君（深圳）制药有限公司;国药集团致君（深圳）坪山制药有限公司
CYHS2602512
Fact date: 2026/10/13 · Site observation date: 2026/10/22
View source ↗ -
2026/09/09Accepted
-
2026/08/14Accepted
济宁神州医药有限公司;安徽佳和药业有限公司
CYHB2601553
Fact date: 2026/08/14 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy